TB Fundamental Analysis - TRIBOO SPA

Fundamental Rating

Overall TB gets a fundamental rating of 1 out of 10. We evaluated TB against 69 industry peers in the Media industry. TB may be in some trouble as it scores bad on both profitability and health. TB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TB has reported negative net income.

TB had a positive operating cash flow in the past year.

In multiple years TB reported negative net income over the last 5 years.

TB had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

TB's Return On Assets of -10.01% is on the low side compared to the rest of the industry. TB is outperformed by 75.00% of its industry peers.

The Return On Equity of TB (-46.00%) is worse than 75.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-10.01%
ROE	-46%
ROIC	N/A

ROA(3y)-5.16%

ROA(5y)-2.73%

ROE(3y)-24.65%

ROE(5y)-13.41%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 96.72%, TB belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.

In the last couple of years the Gross Margin of TB has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for TB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.72%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.87%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for TB remains at a similar level compared to 1 year ago.

TB has less shares outstanding than it did 5 years ago.

TB has a worse debt/assets ratio than last year.

2.2 Solvency

TB has an Altman-Z score of 0.25. This is a bad value and indicates that TB is not financially healthy and even has some risk of bankruptcy.

TB's Altman-Z score of 0.25 is on the low side compared to the rest of the industry. TB is outperformed by 77.94% of its industry peers.

TB has a Debt/Equity ratio of 0.94. This is a neutral value indicating TB is somewhat dependend on debt financing.

TB has a Debt to Equity ratio of 0.94. This is comparable to the rest of the industry: TB outperforms 50.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.94
Debt/FCF	N/A
Altman-Z	0.25

ROIC/WACCN/A

WACC5.09%

2.3 Liquidity

TB has a Current Ratio of 0.80. This is a bad value and indicates that TB is not financially healthy enough and could expect problems in meeting its short term obligations.

TB has a worse Current ratio (0.80) than 63.24% of its industry peers.

TB has a Quick Ratio of 0.80. This is a bad value and indicates that TB is not financially healthy enough and could expect problems in meeting its short term obligations.

TB's Quick ratio of 0.77 is on the low side compared to the rest of the industry. TB is outperformed by 61.76% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.8
Quick Ratio	0.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.50%.

Looking at the last year, TB shows a very negative growth in Revenue. The Revenue has decreased by -17.66% in the last year.

TB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.87% yearly.

EPS 1Y (TTM)-60.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%138.05%

Revenue 1Y (TTM)-17.66%

Revenue growth 3Y-13.12%

Revenue growth 5Y-3.87%

Sales Q2Q%-18.03%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year6.76%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TB. In the last year negative earnings were reported.

Based on the Price/Forward Earnings ratio of 17.48, the valuation of TB can be described as rather expensive.

Compared to the rest of the industry, the Price/Forward Earnings ratio of TB is on the same level as its industry peers.

When comparing the Price/Forward Earnings ratio of TB to the average of the S&P500 Index (23.79), we can say TB is valued slightly cheaper.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	17.48

4.2 Price Multiples

TB's Enterprise Value to EBITDA is on the same level as the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	8.62

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TRIBOO SPA

BIT:TB (1/2/2026, 7:00:00 PM)

0.36

-0.01 (-1.64%)

Chartmill FA Rating

GICS SectorCommunication Services

GICS IndustryGroupMedia & Entertainment

GICS IndustryMedia

Earnings (Last)09-30 2025-09-30

Earnings (Next)03-12 2026-03-12/amc

Inst Owners0.88%

Inst Owner ChangeN/A

Ins Owners56.7%

Ins Owner ChangeN/A

Market Cap10.35M

Revenue(TTM)56.29M

Net Income(TTM)-8.74M

Analysts84.44

Price Target0.49 (36.11%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0.01

Dividend Growth(5Y)-27.05%

DP-4.59%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-54.29%

PT rev (3m)-54.29%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	17.48
P/S	0.18
P/FCF	N/A
P/OCF	5.52
P/B	0.54
P/tB	N/A
EV/EBITDA	8.62

EPS(TTM)-0.31

EYN/A

EPS(NY)0.02

Fwd EY5.72%

FCF(TTM)-0.06

FCFYN/A

OCF(TTM)0.07

OCFY18.13%

SpS1.96

BVpS0.66

TBVpS-0.53

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-10.01%
ROE	-46%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	96.72%
FCFM	N/A

ROA(3y)-5.16%

ROA(5y)-2.73%

ROE(3y)-24.65%

ROE(5y)-13.41%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.87%

GM growth 5YN/A

F-Score3

Asset Turnover0.64

Health

		Industry Rank	Sector Rank
Debt/Equity	0.94
Debt/FCF	N/A
Debt/EBITDA	5.69
Cap/Depr	55.78%
Cap/Sales	6.26%
Interest Coverage	N/A
Cash Conversion	59.5%
Profit Quality	N/A
Current Ratio	0.8
Quick Ratio	0.77
Altman-Z	0.25

F-Score3

WACC5.09%

ROIC/WACCN/A

Cap/Depr(3y)76.16%

Cap/Depr(5y)73.16%

Cap/Sales(3y)7.86%

Cap/Sales(5y)7.33%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-60.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%138.05%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-17.66%

Revenue growth 3Y-13.12%

Revenue growth 5Y-3.87%

Sales Q2Q%-18.03%

Revenue Next Year6.76%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-152.52%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y80.27%

FCF growth 3Y-73.74%

FCF growth 5YN/A

OCF growth 1Y213.29%

OCF growth 3Y-30.09%

OCF growth 5Y-11%

TRIBOO SPA / TB.MI FAQ

What is the fundamental rating for TB stock?

ChartMill assigns a fundamental rating of 1 / 10 to TB.MI.

What is the valuation status for TB stock?

ChartMill assigns a valuation rating of 1 / 10 to TRIBOO SPA (TB.MI). This can be considered as Overvalued.

What is the profitability of TB stock?

TRIBOO SPA (TB.MI) has a profitability rating of 2 / 10.

Is the dividend of TRIBOO SPA sustainable?

The dividend rating of TRIBOO SPA (TB.MI) is 0 / 10 and the dividend payout ratio is -4.59%.

TRIBOO SPA (TB.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TRIBOO SPA / TB.MI FAQ

What is the fundamental rating for TB stock?

What is the valuation status for TB stock?

What is the profitability of TB stock?

Is the dividend of TRIBOO SPA sustainable?